JnJ Posdinemab gets USFDA Fast Track Designation for treatment of Alzheimer's disease Ruchika Sharma9 Jan 2025 1:30 PM ISTPosdinemab is an investigational monoclonal antibody that targets the mid-domain of Alzheimer's disease-specific phosphorylated tau.
JnJ enters licensing agreement for global development, manufacturing, commercialization of STAT6 program from Kaken Pharma Ruchika Sharma27 Dec 2024 10:00 AM ISTNew Brunswick: Johnson & Johnson has announced that it has entered into an exclusive licensing agreement for the global...
JnJ seeks USFDA approval for Simponi to treat pediatric ulcerative colitis Ruchika Sharma19 Dec 2024 12:42 PM ISTDeveloped by Johnson & Johnson, SIMPONI is an anti-TNF biologic medicine that targets and blocks a protein called TNF-alpha.
JnJ seeks USFDA nod for Tremfya for treatment of plaque psoriasis, juvenile psoriatic arthritis in children Ruchika Sharma3 Dec 2024 12:30 PM ISTSpring House: Johnson & Johnson has announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and...
JnJ seeks USFDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis Ruchika Sharma29 Nov 2024 11:30 AM ISTSpring House: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
JnJ MedTech gets IDE approval for OTTAVA Robotic Surgical System Ruchika Sharma15 Nov 2024 5:05 PM ISTNew Brunswick: Johnson & Johnson MedTech has announced that the U.S. Food & Drug Administration (USFDA) has approved the OTTAVA...
USFDA grants Breakthrough Therapy Designation to Nipocalimab for treatment of adults with moderate-to-severe Sjögren's disease: JnJ Ruchika Sharma12 Nov 2024 1:00 PM ISTSpring House: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy...
JnJ seeks approval from USFDA, EMA for DARZALEX FASPRO as subcutaneous monotherapy for high-risk smoldering multiple myeloma Ruchika Sharma10 Nov 2024 4:15 PM ISTRaritan: Johnson & Johnson has announced the submission of regulatory applications to the U.S. Food and Drug Administration (FDA) and...
Shockwave Medical concludes enrollment in all-female coronary IVL study Ruchika Sharma2 Nov 2024 2:16 PM ISTSanta Clara: Shockwave Medical, Inc., part of Johnson & Johnson MedTech has announced the completion of enrollment in EMPOWER CAD, the first...
Johnson and Johnson gets European Commission nod for expanded use of HIV 1 therapy Edurant in younger pediatric patients Ruchika Sharma1 Nov 2024 11:00 AM ISTBeerse: Johnson & Johnson has announced that the European Commission (EC) has approved EDURANT (rilpivirine) for the treatment of HIV-1 infection...
JnJ completes acquisition of V Wave Ruchika Sharma10 Oct 2024 12:34 PM ISTNew Brunswick: Johnson & Johnson has announced that it has successfully completed the acquisition of V-Wave Ltd., a privately-held company...
JnJ to discontinue Phase 2 Field Study evaluating investigational antiviral for Dengue prevention Ruchika Sharma8 Oct 2024 4:50 PM ISTRaritan: Johnson & Johnson has announced it is discontinuing the Phase 2 field study (NCT05201794) evaluating the efficacy of investigational...
